Digital Disclosure of Alzheimer’s Results No Worse Than Telehealth for Distress, Trial Finds
Receiving genetic and biomarker test results for Alzheimer’s disease through a digital platform causes no more anxiety or distress than a telehealth appointment with a clinician, according to a randomized trial published on November 18 in JAMA Neurology.
-
Key Clinical Takeaways:
- Digital disclosure of APOE and p-tau217 results met noninferiority standards compared to clinician-mediated telehealth sessions regarding patient anxiety and disease-related knowledge.
- The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study randomized 651 participants between October 2024 and February 2025.
- Under the US 21st Century Cures Act, patients increasingly access complex medical results directly through online portals without an initial clinician conversation.
Trial Design and Participant Demographics
The decentralized, fully remote eSMARTER trial evaluated alternative scalable delivery models for Alzheimer’s risk information. Enrollment for the study took place from October 2024 through February 2025, with follow-up completed in November 2025.
Participants in the trial ranged in age from 60 to 80 years, with a mean age of 68. The cohort had a mean Montreal Cognitive Assessment (MoCA) score of 19, with approximately 36% scoring below 19. Most participants were women at 67%, and roughly 90% identified as White, as reported by News-Medical.
| Study Arm | APOE Disclosure Count | Primary Focus |
|---|---|---|
| Digital Platform | 435 participants | Patient-controlled online platform or SMS chat |
| Clinician-Mediated | 216 participants | Study clinician or genetic counselor telehealth session |
Disclosure Outcomes and Minor Variations
Researchers analyzed scores on measures of anxiety, disease-specific distress, and disease-related knowledge one to seven days after APOE results were disclosed. Jessica Langbaum, PhD, of the Banner Alzheimer’s Institute in Phoenix, presented the findings at the Clinical Trials on Alzheimer’s Disease conference in Boston.

“We found that learning Alzheimer’s genetic and biomarker information from a digital platform is no less effective — in other words, no worse than — receiving this information from a clinician telehealth visit,” Langbaum told MedPage Today.
Similar noninferiority results emerged when participants were offered optional phosphorylated tau 217 (p-tau217) disclosure six months later. Among APOE4 carriers, three small differences emerged at one to seven days: a greater reduction in disease-specific distress in the telehealth arm, a higher mean negative response to learning risk in the digital group, and slightly higher satisfaction in the telehealth arm.
Digital disclosure was also associated with slightly higher negative responses to learning genetic risk, though those differences were small and did not persist longitudinally. Participants in the APOE ε4 noncarrier subgroup rated telehealth sessions more favorably, with no significant differences in knowledge or psychological outcomes.
Policy Context and Future Portals
Federal regulations mandate that most medical test results be made available to patients without delay.
“This is important given that most patients learn their test results from a report in their patient portal — often a static report or PDF, with limited to no additional information or context about their results and what they mean — and have to wait until their scheduled follow-up appointment to speak with their clinician,” Langbaum pointed out to MedPage Today.
The eSMARTER trial demonstrates that digital disclosure functions as an acceptable alternative to telehealth. Langbaum observed that these results suggest scalable platforms could be developed to integrate directly into patient portals, helping individuals interpret complex biomarker and genetic data.
“We envision that these platforms can be used by clinicians and health systems to better support patients to navigate complex health information,” Langbaum said.
Jessica Langbaum, PhD, of the Banner Alzheimer’s Institute in Phoenix, was not involved in Biogen’s diranersen study. At the Alzheimer’s Association International Conference in London, she described the early findings as “really quite promising if it were to hold up,” while noting “this is early days.” Langbaum also said the results could “reinvigorate interest and investment in lots of tau mechanisms, and the field needs that.”
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.